Acute myeloid leukemia (AML) is the most frequent type of leukemia in adults and has a high mortality burden. Patients over 60 years of age infrequently receive high-intensity chemotherapy. Aim: To describe the clinical characteristics and evaluate the survival in patients with AML, focusing on patients over 60 years. Methods: A retrospective study of patients diagnosed and treated for non-promyelocytic AML at S & oacute;tero del Rio Hospital in Santiago, Chile, between 2015 and 2022. Results: 120 patients with a median age at presentation of 57 years were included. 56% were male-overall survival was 19% at 3 years. The group treated with high-intensity chemotherapy had a survival chance of 35% at 3 years. Sixty-five patients were 60 years or older, of whom 15 received high-intensity chemotherapy with 20% survival at 3 years, which was significantly higher than the non-chemotherapy group, i.e., palliative care (46% vs. 5.2% at 1 year, p-value <0.001). Conclusion: Results with chemotherapy in patients 60 years of age and above are good, but the proportion of patients treated in the age group was low compared to other national reports.